Anixa Biosciences/$ANIX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Anixa Biosciences
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
Ticker
$ANIX
Sector
Primary listing
Employees
4
Headquarters
Website
ANIX Metrics
BasicAdvanced
$93M
-
-$0.32
0.52
-
Price and volume
Market cap
$93M
Beta
0.52
52-week high
$5.46
52-week low
$2.33
Average daily volume
122K
Financial strength
Current ratio
12.176
Quick ratio
11.49
Long term debt to equity
1.091
Total debt to equity
1.394
Profitability
Management effectiveness
Return on assets (TTM)
-40.39%
Return on equity (TTM)
-68.07%
Valuation
Price to book
6.15
Price to tangible book (TTM)
6.15
Price to free cash flow (TTM)
-13.173
Free cash flow yield (TTM)
-7.59%
Free cash flow per share (TTM)
-0.21
Growth
Earnings per share change (TTM)
-19.01%
3-year earnings per share growth (CAGR)
-7.29%
10-year earnings per share growth (CAGR)
-8.59%
What the Analysts think about ANIX
Analyst ratings (Buy, Hold, Sell) for Anixa Biosciences stock.
ANIX Financial Performance
Revenues and expenses
ANIX Earnings Performance
Company profitability
ANIX News
AllArticlesVideos
EXCLUSIVE: Anixa Biosciences' Ovarian Cancer Drug Candidate Shows Longer Survival With No Major Safety Issues
Benzinga·1 month ago
Water Tower Research Publishes Initiation of Coverage Report on Anixa Biosciences, Inc., “Anixa's T-Cell Innovations Show Breakthrough Potential in Solid Tumors”
TheNewswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Anixa Biosciences stock?
Anixa Biosciences (ANIX) has a market cap of $93M as of March 20, 2026.
What is the P/E ratio for Anixa Biosciences stock?
The price to earnings (P/E) ratio for Anixa Biosciences (ANIX) stock is 0 as of March 20, 2026.
Does Anixa Biosciences stock pay dividends?
No, Anixa Biosciences (ANIX) stock does not pay dividends to its shareholders as of March 20, 2026.
When is the next Anixa Biosciences dividend payment date?
Anixa Biosciences (ANIX) stock does not pay dividends to its shareholders.
What is the beta indicator for Anixa Biosciences?
Anixa Biosciences (ANIX) has a beta rating of 0.52. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.